Showing all posts written by Raj Pai

Raj Pai
Raj Pai
Raj D. Pai's practice focuses on patent prosecution and litigation in the pharmaceutical, biotechnology, and the medical device sectors.
Prior to joining the firm, Raj worked as a post-doctoral fellow at the University of Southern California and the University of California-Los Angeles. His work included analyzing signaling pathways in leukemic cells, parasitology studies, and biofuel production. He holds a Ph.D. from the University of California Berkeley, where he carried out biochemical and structural studies on the bacterial ribosome.
Raj attended the University of California Davis School of law. While in law school he served as an articles selection editor for the Business Law Journal and served as President of the King Hall Intellectual Property Law Association.
Raj worked as a summer associate at the firm in 2016 and joined the firm in 2017.

Veterans Association and IBM Watson Extends Oncology Partnership

On July 19th, 2018, the United States Department of Veterans Affairs (VA) and IBM Watson Health announced an extension of their ongoing partnership to interpret cancer data in patients.

According to the press release, the partnership

Theranos Charges Provide Perspective for Medical Device Companies, Biotechnology Companies, and Investors

On March 14, 2018, the Securities and Exchange Commission (SEC) announced it filed charges against the founder and CEO of Theranos Inc., Elizabeth Holmes, and its former president, Ramesh Balwani.

Theranos describes itself as a privately

Wright Medical Group N.V. announces $88 million Acquisition of IMASCAP SAS

Wright Medical Group recently announced the acquisition of IMASCAP SAS for $88 million. According to the press release, Wright Medical Group (NASDAQ: WMGI) is a publicly traded company focusing on extremity joint replacement and bio-orthopedic